One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …

Abstract Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib,
which target RAF and the downstream MAP–ERK kinase (MEK) 1 and MEK2 kinases …

Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients
develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a …

Background: MEK1 mutations in melanoma can confer resistance to BRAF inhibitors,
although preexisting MEK1P124 mutations do not preclude clinical responses. We sought to …

Most patients with BRAF V600-mutant metastatic melanoma develop resistance to selective
RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF …

Targeted BRAF inhibition (BRAFi) and combined BRAF and MEK inhibition (BRAFi and
MEKi) therapies have markedly improved the clinical outcomes of patients with metastatic …

BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …

BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with
advanced V600E/K BRAF melanomas. Somatic activating MEK1 mutations are thought to be …

Background The clinical use of BRAF inhibitors for treatment of metastatic melanoma is
limited by the development of drug resistance. In this study we investigated whether co …

Background The sustained clinical activity of the BRAF inhibitor vemurafenib
(PLX4032/RG7204) in patients with BRAFV600 mutant melanoma is limited primarily by the …